New York, USA – July 28, 2020 – Acrocell, the division of Creative Bioarray, is a leading global provider of high-quality services in the field of pharmaceutical and biotechnology industries, including cardiac and neuron safety analysis and translational analysis. Recently, Acrocell announces the release of its hERG (Ikr, Kv11.1) channel in order to evaluate the effects of compounds on hERG activity early in drug discovery, thereby reducing the risk of putting extensive efforts in cardiotoxic drugs and accelerate the drug development.
Cardiovascular complications caused by drugs limit the use of many successful clinical treatments, such as anticancer therapies. During the entire process of new drug development, tremendous efforts and investments have been made to identify the adverse effects of the cardiovascular system and minimize the risk of patients. Approximately one-third of the compounds in preclinical development show some degree of heart disease risk.
One of the most important cardiovascular (CVS) responsibilities in safety pharmacology is a life-threatening disease called Torsades de pointes (TdP), which is mainly mediated by changes in the activity of hERG (Kv11.1) channels and other important cardiac ion channels. Acroscell is composed of a group of experts with many years of experience in ion channel safety determination and cardiotoxicity assessment. It can provide electrophysiological services for in vitro determination, including hERG safety evaluation.
Acroscell has developed GLP-compliant in vitro electrophysiology services, which can provide customers with a powerful ion channel platform from which the mechanism and safety of lead compounds can be characterized. By evaluating its ability to block the hERG channel in vitro and extend the QTc interval between ventricular repolarization and ECG, Acroscell effectively eliminates the risk of approving drugs that may produce TdP in patients. With traditional patch-clamp and MEA technology, Acroscell can provide services to detect and analyze the effects of candidate drugs on key cardiac ion channels and pathways with predictable and reproducible data.
Acroscell utilizes the most advanced automated QPatch-HT system to provide higher throughput hERG safety analysis at a lower cost, and better consistency. For a small number of compounds or compounds identified using QPatch, Acroscell is capable to perform regular whole-cell patch clamp assays to obtain detailed mechanism information, and the GLP-level hERG safety analysis can provide high-quality data for registration.
“Acroscell provides manual and automatic patch-clamp functional hERG analysis to evaluate the inhibitory or enhancement effect of drugs on hERG channels. In this assay, CHO-hERG cells or HEK293-hERG cells are used to specifically evaluate the effect of the test compound on the hERG channel. The pre-compound and post-compound currents were measured by patch-clamp and used in the calculation of hERG inhibition,” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “Our experienced technicians enable us to provide customized detection methods. We can adjust the test according to the detailed requirements from the customers.”
As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.